Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.

Journal: Journal of arrhythmia
Published Date: Sep 15, 2015

Abstract

BACKGROUND: Although patients taking non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine coagulation monitoring, high-risk patients require monitoring to assess pharmacodynamics.

Authors

  • Kozue Ikeda
    Department of Cardiology, Shinoda General Hospital, 2-68 Sakura-cho, Yamagata, Yamagata Prefecture 990-0045, Japan.
  • Hideaki Tachibana
    Department of Cardiology, Shinoda General Hospital, 2-68 Sakura-cho, Yamagata, Yamagata Prefecture 990-0045, Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals